Indegene board approves financials, ESOP, and €8.5m subsidiary investment

Indegene Limited announced its board of directors approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The board also approved the allotment of shares under the ESOP 2020 Plan and RSU 2020 Plan, and noted grants under the RSU 2020 Plan, ESOP 2020 Plan, and CSOP 2022. An amendment to the anti-sexual harassment policy was also approved.

A significant investment was approved for Indegene Ireland Limited, a wholly-owned subsidiary, up to €8.5 million. This investment will support its capex requirement and business expansion and is planned for completion by December 31, 2026. Indegene Ireland Limited generated a turnover of €739,163 for the financial year ended March 31, 2025. The company will subscribe to equity shares with a face value of €1 each, at a premium determined by a valuation report.